Navigation Links
Orbsen Therapeutics Moves Into New Headquarters in Galway, Ireland
Date:4/4/2019

Orbsen Therapeutics, a biotechnology company focused on the discovery, development and commercialization of first-in-class stromal cell immunotherapies, announced it will move its base of operations from the National University of Ireland (NUI) Galway campus to become the anchor tenant at the University’s newly created biotechnology park in Galway, Ireland.

“With four clinical trials in full swing and the closing of additional funding rounds to support the development of our novel therapies, we simply needed additional space to accommodate our increasing staff and prepare for our next phase of growth,” said Dr. Larry Couture, CEO of Orbsen Therapeutics. “The move reflects the progress we are making in the development of our therapies, bringing them one step closer to addressing some of today’s most challenging diseases.”

Orbsen Therapeutics’ new global headquarters will combine laboratory and office space on two levels of the park’s inaugural three-story building.

“We are delighted Orbsen Therapeutics was set in motion at NUI Galway and will continue its exciting expansion here in our region,” said David Murphy, Director of the Innovation Office at NUI Galway. “Generating and supporting regional development is central to the University’s strategy. Currently, NUI Galway supports more than 40 companies on campus. Extending the University’s incubation eco-system will allow us to amplify efforts and enable even more start-up companies to innovate and grow.”  

Orbsen’s proprietary ORBCEL™ immunotherapy yields nearly 100 percent pure stromal cells, a significant increase in purity when compared to first generation stromal cell therapies.

Orbsen currently is enrolling and treating patients in four clinical trials to assess ORBCEL’s safety and efficacy in the prevention and treatment of diabetic kidney disease, non-healing diabetic foot ulcers, moderate to severe acute respiratory distress syndrome (ARDS) and in patients with primary sclerosis cholangitis (PSC) and autoimmune hepatitis. A fifth trial is pending for patients with several auto-immune disorders.

Orbsen’s new headquarters will be the hub of operations to coordinate research, operations, product development and clinical development.

About Orbsen Therapeutics

Orbsen Therapeutics, Ltd. is a leading company in the development of cellular immunotherapies across four immune-mediated inflammatory conditions. Founded in 2006, Orbsen Therapeutics Ltd., is a privately held company led by global leaders in the field of cellular immunotherapy. The company, which spun-out from Ireland’s Regenerative Medicine Institute at the National University or Ireland Galway, has developed proprietary technologies that enables the isolation of a well characterized population of pure stromal cells from human tissues which, once isolated, can be expanded and frozen to generate multiple doses of a high-margin, “off the shelf” therapeutic product.

For more information visit: http://www.orbsentherapeutics.com

Read the full story at https://www.prweb.com/releases/orbsen_therapeutics_moves_into_new_headquarters_in_galway_ireland/prweb16211996.htm.


'/>"/>
Source: PRWeb
Copyright©2019 Vocus, Inc.
All rights reserved


Related biology news :

1. Orbsen Therapeutics' NEPHSTROM Clinical Trial Underway at Four European Union Locations
2. Nativis Announces Name Change To EMulate Therapeutics, Inc.
3. uBiome Receives Patent for Microbiome-Derived Diagnostics and Therapeutics for Immune-Microbial Dysfunction
4. RoosterBio Inc. and Tissue Regeneration Therapeutics Inc. Announce Alliance Around Scale-up Manufacturing of Umbilical Cord Tissue Perivascular Cell Technology
5. Cybrexa Therapeutics Expands Scientific Advisory Board Ahead of IND Filing
6. Genedata Announces Aptevo Therapeutics Deploys Genedata Biologics to Streamline Cancer Immunotherapy R&D
7. Spero Therapeutics Acquires Next Generation Antibacterial Candidates from Pro Bono Bio for Treatment of Multidrug-Resistant, Gram-Negative Infections
8. MicroRNA: An Insight to miRNA-based microarrays, diagnostics and therapeutics Overview, Cambridge Healthtech Advisors
9. Eureka Therapeutics raises $21 million in series c to expand cancer immunotherapy pipeline
10. Study shows Hera Therapeutics compound combats HPV types that cause most cervical cancer
11. Human Longevity, Inc. and Celgene Cellular Therapeutics Sign License Agreement to Develop and Commercialize Placental Stem Cell Population, PSC-100 for Multiple Therapeutic Applications
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/31/2019)... ... May 30, 2019 , ... Researchers from Ambry Genetics ... significant differences in the prevalence of hereditary genetic mutations, also called germline mutations, ... women. Results will be presented at the 2019 American Society of Clinical Oncology ...
(Date:5/24/2019)... ... , ... The newest edition of Crystallography Times from Rigaku ... , Crystallography Times is a monthly electronic newsletter published by Rigaku Oxford Diffraction ( ... by presenting the latest news and crystallographic research. , “Crystallography in the News” ...
(Date:5/21/2019)... ... May 21, 2019 , ... If a ... know? How can we tell it apart from the millions of microorganisms that ... multi-institution research team, including Eric Young , assistant professor of chemical engineering ...
Breaking Biology News(10 mins):
(Date:6/11/2019)... ... 2019 , ... Veterinary Regenerative Medicine company, VetStem Biopharma ... that their GMP facility for cell production is now approved by the California ... an important milestone for VetStem as it expands into contract cell manufacturing services. ...
(Date:5/31/2019)... ... May 29, 2019 , ... ... the USPTO providing proprietary interest to our methodology, processes, and diagnostic techniques. ... AND TREATMENT… extends Somnology’s IP rights including our proprietary sleep scoring methodology. ...
(Date:5/22/2019)... (PRWEB) , ... May 22, 2019 , ... Artemis ... closed a $8 million Series A funding round co-led by Astanor Ventures ... Empire State Development Fund and iSelect Fund . The company has raised ...
(Date:5/14/2019)... ... May 13, 2019 , ... Leak Detection Associates (LDA), the ... Biotechnology, Medical Device and Food Packaging Industries’ is excited to announce the go-live ... LDA’s ability to communicate directly with the marketplace; serving as a destination to ...
Breaking Biology Technology: